Swiss Rockets

What Swiss Rockets does

Swiss Rockets AG, founded in 2018 and headquartered in Basel, Switzerland, is a privately held biotech incubator and accelerator that builds and operates a portfolio of specialized subsidiary companies spanning targeted cancer therapies, radioligand therapies, next-generation vaccines, radioisotope supply, and — following its February 2026 acquisition of Complete Genomics — genomic sequencing technology. Its core therapeutic platforms include bimiralisib, a dual PI3K/mTOR inhibitor under Torqur AG targeting actinic keratosis, prostate cancer, and head and neck cancer; Terbium-161 (Tb-161) radioligand therapies under Torpedo Pharmaceuticals AG, with lead candidate TRP-001 (161Tb-PSMA) for prostate cancer and evidence of 2.4x higher tumor radiation dose versus the Lutetium-177 standard; intranasal needle-free COVID-19 vaccines under Rocketvax AG; and Tb-161 production and purification under Rocket Isotopes AG with secured access to Gadolinium-160 raw material and nuclear reactor collaborators. The group's genomics arm, anchored by Complete Genomics and the CoolMPS antibody-based sequencing chemistry licensed from MGI Tech, sells the DNBSEQ-T7+ high-throughput sequencer (US list price $800,000) and is preparing the CoolMPS 600 mid-throughput sequencer for Q2 2026 with a sub-$100/WGS target price.

The business model is multi-stream and primarily B2B/enterprise: (1) licensing and royalties from therapeutic IP (e.g., CoolMPS licensing deal expected to generate at least $120 million in upfront, milestone, and royalty payments); (2) sequencing hardware and reagent sales via Complete Genomics to research institutions, clinical labs, and production sequencing environments; (3) contract manufacturing and supply of Tb-161 isotopes both internally and to future external radiopharmaceutical developers; (4) eventual product sales from late-stage portfolio candidates through pharmaceutical partnerships. Go-to-market combines direct enterprise sales, OEM/manufacturing partnerships (Lonza for bimiralisib, Alloy Therapeutics for radioligand discovery), conference-led scientific marketing (AGBT, Theranostics World Congress), and earned-media-driven investor relations. Customer segments are hospitals, oncology centers, radiopharmacies, genomics service providers, and large-scale WGS programs. The company maintains regional subsidiaries in the US (Swiss Rockets Inc., Boston) and Serbia (Swiss Rockets doo Serbia) and operates manufacturing partnerships with Lonza in Visp and Nansha.

Name

Swiss Rockets

Legal name

Swiss Rockets AG

Website

https://swissrockets.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Swiss Rockets AG is a Basel-based biotech incubator founded in 2018 that builds and operates portfolio companies developing targeted cancer therapies, Terbium-161 radioligand therapies, intranasal vaccines, and genomic sequencing platforms for pharmaceutical, clinical, and research customers globally.

Ownership category

akta.pro rank

Product category

Biotechnology & Radiopharmaceutical Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Biotech incubator accelerator
• Radioligand therapy
• Oncology drug development
• Genomic sequencing platforms
• Vaccine development

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Therapeutic Development & Licensing: Swiss Rockets generates revenue through developing and commercializing proprietary therapeutics including radioligand therapies, PI3K/mTOR inhibitors, and vaccines. Revenue flows from licensing deals, milestone payments, and eventual product sales through its portfolio companies.
2. Genomics Technology Sales & Licensing: Following the Complete Genomics acquisition, Swiss Rockets generates revenue from selling genomic sequencing platforms, reagents, and software, with CoolMPS technology licensed globally outside Asia-Pacific. The deal with MGI is expected to generate at least $120 million in licensing fees including upfront, milestone, and royalty payments.
3. Radioisotope Supply: Rocket Isotopes AG produces and supplies Terbium-161 to both internal portfolio companies (Torpedo Pharmaceuticals) and external radiopharmaceutical developers, creating potential long-term revenue from isotope sales and manufacturing partnerships.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Swiss Rockets AG is a Basel-based biotech incubator and accelerator founded in 2018 that develops and commercializes targeted cancer therapies, radioligand therapies, next-generation vaccines, and genomic sequencing technologies through a portfolio of wholly-owned subsidiaries. The group develops dual PI3K/mTOR inhibitors (bimiralisib) for actinic keratosis and oncology, Terbium-161-based radioligand therapies (TRP-001) for prostate cancer and solid tumors, needle-free intranasal COVID-19 vaccines, and high-throughput and mid-throughput genomic sequencing platforms (DNBSEQ-T7+ and CoolMPS 600) following the Complete Genomics acquisition in 2026.

Product overview

Swiss Rockets Group is a biotech incubator and accelerator with a portfolio of specialized subsidiary companies spanning targeted cancer therapies, radioligand therapeutics, and next-generation vaccines. The group includes Rocketvax AG (intranasal COVID-19 vaccines), Torqur AG (PI3K/mTOR inhibitors including bimiralisib), Torpedo Pharmaceuticals AG (Terbium-161 radioligand therapies with lead candidate TRP-001), and Rocket Isotopes AG (radioisotope supply). Following the acquisition of Complete Genomics in 2026, the group also operates genomic sequencing platforms including DNBSEQ-T7+ (high-throughput) and CoolMPS 600 (mid-throughput). The portfolio ranges from preclinical to Phase III across oncology, infectious diseases, and dermatology.

Differentiator

Problem solved

Functional benefit

Brands

• Rocketvax: Next-generation vaccine development company focused on infectious diseases and COVID-19 variants.
• Torqur
• Torpedo
• Rocket Isotopes
• CoolMPS

Products and services

• Rocketvax AG — Next-Generation Intranasal Vaccine Program Subsidiary program developing needle-free intranasal vaccines that induce local immunity at the upper respiratory tissues, with broad and long-lasting immunity against current and future SARS-CoV-2 variants. Targets healthcare systems, public health authorities, and pandemic preparedness programs seeking alternatives to injectable COVID-19 vaccines.
• Torqur AG — Dual PI3K/mTOR Inhibitor Program (Bimiralisib) Subsidiary program developing next-generation dual PI3K/mTOR inhibitors for oncology and dermatology applications, including bimiralisib (PQR309) in topical form for actinic keratosis and oral formulations for prostate cancer and head and neck cancer. Targets dermatology clinics and oncology practices.
• Torpedo Pharmaceuticals AG — Terbium-161 Radioligand Therapy Program (TRP-001) Subsidiary program developing next-generation radioligand therapies using Terbium-161 (Tb-161), including the lead candidate TRP-001 (161Tb-PSMA) targeting early-stage prostate cancer. Tb-161 delivers 2.4x higher tumor radiation dose than Lutetium-177 while maintaining comparable safety. Targets hospitals, cancer treatment centers, and oncology practices.
• Rocket Isotopes AG — Terbium-161 Radioisotope Supply Subsidiary producing and supplying Terbium-161 (Tb-161) radioisotope with a proprietary semi-automated in-house purification process delivering high-purity Tb-161 suitable for radiolabeling at high specific activities. Supplies the internal portfolio company Torpedo Pharmaceuticals AG and intends to support external radiopharmaceutical developers as production capacity expands. Includes secured access to Gadolinium-160 raw material and nuclear reactor irradiation partnerships.
• DNBSEQ-T7+ High-Throughput Sequencing Platform High-throughput genomic sequencing platform generating 48 billion reads from four independent flow cells within 24 hours. Supports large-scale whole genome sequencing, population genomics, and clinical research with Q40 per-base accuracy at $1 per gigabase. Processes over 28,000 whole genomes per year. Operated by Complete Genomics (wholly-owned subsidiary). US list price $800,000.
• CoolMPS 600 Mid-Throughput Sequencer Mid-throughput sequencer utilizing proprietary antibody-based CoolMPS chemistry combined with DNBSEQ technology. Enables cost-effective extended single-end sequencing to 600 bases (SE600) with 2.4 terabases throughput per run. Designed to enable sub-$100 whole genome sequencing when fully utilized, making genome sequencing accessible beyond centralized ultra-high-throughput centers. Availability planned for Q2 2026.
• TRP-001 (161Tb-PSMA) — Lead Radioligand Therapy Drug Candidate Drug candidate in preclinical-to-clinical-stage development by Torpedo Pharmaceuticals AG: 161Tb-PSMA radioligand therapy for early-stage prostate cancer. Uses Terbium-161 which delivers 2.4x higher radiation dose to tumors than Lutetium-177 while maintaining comparable safety. Targets over 3 million men in the US affected by prostate cancer.
• Bimiralisib (PQR309) — Dual PI3K/mTOR Inhibitor Drug Candidate Dual pan PI3K/mTOR inhibitor drug candidate in late-stage clinical development preparation by Torqur AG. Targets actinic keratosis (topical formulation) and prostate cancer and head and neck cancer (oral formulation). Backed by Lonza manufacturing partnership for technology transfer, process optimization, and cGMP manufacturing of highly potent APIs. Addresses current standard-of-care recurrence rate up to 58% in actinic keratosis.

Quantifiable outcome

• Terbium-161 delivers 2.4x higher radiation dose to tumors compared to Lutetium-177 while maintaining similar safety profile
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• LonzacoreStrategic or Co-development Partner · 31 March 2026Manufacturing agreement for clinical supply of bimiralisib, Torqur's investigational dual PI3K/mTOR inhibitor. Lonza provides technology transfer, process optimization, and cGMP manufacturing services for highly potent active pharmaceutical ingredients at facilities in Nansha (China) and Visp (Switzerland). Supports advancement of actinic keratosis and oncology development programs.
• MGI Tech Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 29 October 2025MGI Tech and Complete Genomics granted Swiss Rockets an exclusive perpetual, transferable, and sublicensable license to develop and manufacture the CoolMPS sequencing platform outside of Asia-Pacific and Greater China. The agreement covers USA, Europe, Latin America, Africa, and Central Asia, with option to expand into Asia-Pacific. Technology transfer provisions included with revenue-based royalties. Deal expected to generate at least $120 million in licensing fees.
• Emergent BioSolutionsminorStrategic or Co-development Partner · 12 March 2025Emergent BioSolutions announced an investment and strategic partnership with Rocketvax Ltd for vaccine research, manufacturing, and commercialization. Collaboration involves developing vaccine candidates including nasal spray SARS-CoV-2 vaccine, supported by a letter of intent with NIH.
• Alloy Therapeutics, Inc.coreStrategic or Co-development Partner · 12 January 2025Master Research Agreement establishing multi-target collaboration to discover and develop next-generation radioligand therapeutics for oncology executed through Swiss Rockets subsidiary Torpedo Pharmaceuticals AG. Alloy provides antibody discovery and engineering platforms while Torpedo contributes radioisotope and radiopharmaceutical development expertise including Terbium-161, to advance candidates toward clinical development.
• Nuclear reactor collaborators (unspecified)coreTechnology or IntegrationRocket Isotopes AG has confirmed nuclear reactor collaborations to ensure scalable manufacturing capacity for Terbium-161 production. Reactor irradiation partners supplement Rocket Isotopes' semi-automated in-house purification process for high-purity Tb-161.
• Gadolinium-160 raw material suppliers (unspecified)coreTechnology or IntegrationRocket Isotopes AG has secured access to Gadolinium-160, the essential raw material for Terbium-161 production, as part of its supply chain strategy for Tb-161 manufacturing.

Scale indicators9 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Illumina: Dominant incumbent in next-generation DNA sequencing. Relevant broad incumbent peer against whom CoolMPS-enabled Complete Genomics must compete for ex-Asia-Pacific sequencing share.
• Novartis: Owns Pluvicto (lutetium-177 PSMA), the incumbent radioligand therapy that TRP-001 (161Tb-PSMA) would need to displace in prostate cancer. Novartis is a broad pharmaceutical incumbent whose radioligand franchise defines the current standard of care Swiss Rockets' Tb-161 platform is targeting.
• Roivant Sciences: Multi-asset biotech company operating multiple subsidiary 'Vants' that develop distinct therapeutic programs. Relevant broader-incumbent peer for the model of operating a portfolio of focused biotech entities under one parent.

Direct peers

• MGI Tech: Sequencing technology company and Swiss Rockets' CoolMPS licensing counterparty. Direct peer in next-generation sequencing platforms and a strategic relationship partner that competes with the DNBSEQ-T7+ and CoolMPS 600 in Asia-Pacific.
• Telix Pharmaceuticals: Listed radiopharmaceutical company developing PSMA imaging and therapeutic agents; operates both drug and isotope supply businesses. Direct peer in radioligand therapy commercialization and nuclear medicine infrastructure.
• Lantheus Holdings: Radiopharmaceutical company with PSMA-directed products and a portfolio across diagnostic and therapeutic radioligands. Direct peer to Torpedo Pharmaceuticals AG given overlapping prostate cancer imaging/therapy franchise and radioisotope supply chain involvement.
• PureTech Health: Boston-listed biotech R&D engine that founds and develops therapeutic candidates around a shared operational platform. Most direct listed analog to Swiss Rockets' incubator/accelerator model with multi-subsidiary clinical assets.
• ITM Isotope Technologies Munich: Manufacturer of medical radioisotopes and developer of targeted radioligand therapies. Direct peer in supplying therapeutic radioisotopes (including non-Lu-177 emitters) and pairing them with proprietary targeting vectors.

Emerging players

• POINT Biopharma (acquired by Eli Lilly): Radiopharmaceutical company developing PSMA-targeted radioligand therapies (PNT2002) prior to its acquisition by Eli Lilly. Direct comparator in next-generation PSMA radioligand development and a relevant reference point for clinical and commercial scale-up.
• ARTBIO: Emerging radioligand therapy company developing alpha-emitter-based therapies. Conceptually adjacent peer also targeting the displacement of Lu-177-based radioligand therapies with alternative medical radioisotopes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/SwissRockets
• Instagraminstagram.com/swissrockets
• LinkedInlinkedin.com/company/swiss-rockets-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles28 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Swiss Rockets